TABLE 2.

Drugs with potential benefit in PTSD and mechanism of action.

Drug	Action mechanism	References
Amiloride	ASIC1a antagonist	Pidoplichko et al. (2014); Battaglia et al. (2019)
Fluvoxamine	Sig-1R agonist	Herrera et al. (2008)
ARBs/ACEi	Downregulate ANGII, upregulate BDNF and AQP-4, lower PAI-1 and ROS,	Fogari and Zoppi (2006); Matsushita et al. (2010); Dikalov and Nazarewicz (2013); Baluta and Vintila (2015); Ishrat et al. (2015); Chen et al. (2017c); Andhavarapu et al. (2021); Hashimoto (2021)
Ebselen	Peroxynitrate scavenger	Chen et al. (2007); Amporndanai et al. (2021)
NO	Furin inhibitor	Wolf and Morrison (2017)
Diminazene	Furin inhibitor, ASIC1a antagonist	Qaradakhi et al. (2020)
Spironolactone	Furin inhibitor	Schmidt et al. (2017)
Statins	PAI-1 inhibitors	Kellici et al. (2021)
BDNF (via MIND)	TrkB agonist	Padmakumar et al. (2021)
7,8-dihydroxyflavone	TrkB agonist	Sanz-García et al. (2016)
Lithium	TrkB agonist	Forster et al. (1995)
LM22A-4	TrkB agonist	Forster et al. (1995)
Fluoxetine	AQP-4 upregulation	Di Benedetto et al. (2016)
SS-31	Mitochondrial antioxidant	Tarantini et al. (2018)
Propranolol	Glycolysis inhibitor	Vaiva et al. (2003); Ganji and Reddy (2021)
Dichloroacetate (DCA)	Glycolysis inhibitor, mitochondrial protector	Kho et al. (2019)
Brexanolone	Mitochondrial and BBB protector	Pineles et al. (2018); Morrison et al. (2019)
Progesterone	NO upregulation?	Balan et al. (2019); Ney et al. (2019)
JQ1/SF2523	Senolytics, BRD inhibitors	Go et al. (2021)
Trauma-focused psychotherapy	T-cell enhancer	Morath et al. (2014)